Nautilus Neurosciences - CAMBIA® was acquired by Assertio Therapeutics on December 17, 2013
medical products Company

Out of 60 sectors in the Mergr database, medical products ranked 13 in number of deals in 2013. The largest medical products acquisition in 2013 was Bausch & Lomb - which was acquired by Bausch Health Companies for $8.7B.

Join Mergr to view all 183 acquisitions of medical products companies in 2013, including 23 acquisitions by private equity firms, and 160 by strategics.

Nautilus Neurosciences - CAMBIA® (Diclofenac Potassium for Oral Solution)


United States,

Nautilus Neurosciences - CAMBIA® (Diclofenac Potassium for Oral Solution) is a non-steroidal anti-inflammatory drug (NSAID) indicated for acute treatment of migraine attacks with or without aura in adults 18 years of age or older.

Medical Products M&A - Last 3 Years

Nautilus Neurosciences - CAMBIA® was acquired by Assertio Therapeutics on December 17, 2013.

Join Mergr to view this profile - and discover more medical products acquisitions of companies like Nautilus Neurosciences - CAMBIA®.


What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.7K Private Equity Firms
  • 132K M&A Transactions
  • 141K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.0K M&A Advisors
    (Investment Banks and Law Firms)
  • 37K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.